ABBISKO-B(02256): Hony Medicine presented six research advances at the 2026 AACR Annual Meeting, focusing on pan-KRAS, fourth-generation EGFR, and synthetic lethality as innovative pathways.

ABBISKO-B (02256) announced that Hony Medicine presented six latest preclinical and translational research results in poster form at the American Association for Cancer Research (AACR) 2026 Annual Meeting in San Diego, USA, from April 17 to 22. These reports cover several core innovative areas of the company, including the panKRAS inhibitor ABSK211, the fourth-generation EGFR inhibitor ABK-EGFR-1, the CDK4 selective inhibitor ABK-CDK4, the PRMT5-MTA synergistic inhibitor ABSK131, and a study analyzing the resistance mechanism of the FGFR2/3 inhibitor ABSK061 based on ctDNA technology. The research results showed that ABSK211 can significantly enhance the anti-tumor effect through multiple mechanisms, providing support for the development of various combination therapy strategies in clinical development. The results support further development of ABK-EGFR-1 as the next generation targeted therapy drug for EGFR-resistant tumors, particularly suitable for patients with brain metastases. ABK-CDK4 is expected to overcome the key limitations of current CDK4/6 inhibitors and provide a differentiated therapeutic option. ABSK131 is expected to become a core foundation therapy in combined treatment strategies for MTAP-deficient tumors. Hony Medicine concentrated on showcasing the latest preclinical and translational research progress of multiple product pipelines at the 2026 AACR Annual Meeting, demonstrating the company's strong capabilities in early drug discovery and development. As the early pipelines gradually enter clinical stages, the company is continuously improving its globally competitive research and development platform. In the future, Hony Medicine will continue to focus on unmet clinical needs, accelerate the translation of innovative outcomes into clinical applications, and bring more innovative therapies with first-in-class and best-in-class potential to patients worldwide.